Welcome to our dedicated page for Cellebrite DI Ltd. SEC filings (Ticker: CLBT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cellebrite DI Ltd. SEC filings document its foreign private issuer reporting for an AI-powered digital investigative and intelligence software business. Form 6-K current reports furnish quarterly and annual results releases, GAAP financial tables incorporated by reference into Form S-8 and Form F-3 registration statements, and annual general meeting voting results under the Israeli Companies Law and the company’s articles of association.
The filing record also includes Form 20-F annual reporting, which provides the recurring public-company framework for Cellebrite’s business, financial reporting and ordinary-share governance disclosures.
Form 144 notice for proposed sale of securities by an insider or affiliate. The filing reports an intended sale of 25,810 shares of Common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $454,514.10. The shares are listed on NASDAQ and the approximate sale date provided is 09/22/2025. The shares were acquired as restricted stock units from the issuer on 02/15/2023, and no related securities sales were reported in the prior three months. Several filer and issuer identification fields are left blank in the supplied content.
Cellebrate DI Ltd. reports that shareholders approved all proposals presented at its annual general meeting of shareholders held on September 19, 2025. These proposals were adopted by the requisite majority in accordance with Israeli law and the company’s articles, as outlined in the proxy statement previously provided to investors.
The meeting had strong participation, with 188,039,771 ordinary shares represented, equal to approximately 76.82% of issued and outstanding ordinary shares as of the record date. This report is also incorporated by reference into Cellebrite’s existing registration statements on Form S-8 and Form F-3.
Cellebrite DI Ltd. (CLBT) filed a Form 144 reporting a proposed sale of 27,166 common shares with an aggregate market value of $481,313.61. The shares represent a small fraction of the 244,469,106 shares outstanding and are scheduled for sale on or about 09/19/2025 on NASDAQ. The shares were acquired as restricted stock from the issuer on 02/14/2025, 05/14/2025, and 08/14/2025, totaling 27,166 shares. The filing also discloses a sale during the past three months of 12,878 shares on 09/11/2025 for gross proceeds of $225,743.61. The document includes the required signer representation that no undisclosed material adverse information exists.